Literature DB >> 27057291

Carotid Baroreceptor Stimulation and Arteriovenous Shunts for Resistant Hypertension.

Nicholas Paivanas1, John D Bisognano1, John P Gassler1.   

Abstract

Pharmacologic therapy for hypertension is effective for the majority of patients with hypertension, but there is a subset of the population with treatment-resistant hypertension who cannot achieve their blood pressure goal despite taking multiple medications. Since these patients are at increased risk of cardiovascular disease and end-organ damage, additional therapies must be considered. This review discusses several novel interventional therapies-including baroreflex activation therapy, baroreceptor stenting, and creation of an arteriovenous shunt-that may provide alternative options for blood pressure control in those with treatment-resistant hypertension. All of these therapies remain investigational, and each has its own strengths and weaknesses that will be critical to assess as they come to market.

Entities:  

Keywords:  Rheos Pivotal Trial; arteriovenous shunt; baroreflex activation therapy; carotid nitinol stent; treatment-resistant hypertension

Mesh:

Substances:

Year:  2015        PMID: 27057291      PMCID: PMC4814008          DOI: 10.14797/mdcj-11-4-223

Source DB:  PubMed          Journal:  Methodist Debakey Cardiovasc J        ISSN: 1947-6108


  20 in total

Review 1.  Current status of lumbar sympathectomy.

Authors:  T R Allen
Journal:  Am Surg       Date:  1976-02       Impact factor: 0.688

2.  Percutaneous femoral arteriovenous shunt creation for advanced chronic obstructive pulmonary disease: a single-center safety and efficacy study.

Authors:  Stefan C Bertog; Christina Kolmer; Swetlana Kleschnew; Jennifer Franke; Nina Wunderlich; Peter Kardos; Horst Sievert
Journal:  Circ Cardiovasc Interv       Date:  2012-02-07       Impact factor: 6.546

3.  The influence of supradiaphragmatic splanchnicectomy on the heart in hypertension.

Authors:  E M ISBERG; M M PEET
Journal:  Am Heart J       Date:  1948-04       Impact factor: 4.749

4.  Surgical treatment of hypertension.

Authors:  R H SMITHWICK
Journal:  Am J Med       Date:  1948-05       Impact factor: 4.965

5.  Central arteriovenous anastomosis for the treatment of patients with uncontrolled hypertension (the ROX CONTROL HTN study): a randomised controlled trial.

Authors:  Melvin D Lobo; Paul A Sobotka; Alice Stanton; John R Cockcroft; Neil Sulke; Eamon Dolan; Markus van der Giet; Joachim Hoyer; Stephen S Furniss; John P Foran; Adam Witkowski; Andrzej Januszewicz; Danny Schoors; Konstantinos Tsioufis; Benno J Rensing; Benjamin Scott; G André Ng; Christian Ott; Roland E Schmieder
Journal:  Lancet       Date:  2015-01-23       Impact factor: 79.321

6.  Global burden of hypertension: analysis of worldwide data.

Authors:  Patricia M Kearney; Megan Whelton; Kristi Reynolds; Paul Muntner; Paul K Whelton; Jiang He
Journal:  Lancet       Date:  2005 Jan 15-21       Impact factor: 79.321

7.  Cardiovascular outcome in treated hypertensive patients with responder, masked, false resistant, and true resistant hypertension.

Authors:  Sante D Pierdomenico; Domenico Lapenna; Anna Bucci; Roberta Di Tommaso; Rocco Di Mascio; Bianca M Manente; Maria P Caldarella; Matteo Neri; Franco Cuccurullo; Andrea Mezzetti
Journal:  Am J Hypertens       Date:  2005-11       Impact factor: 2.689

Review 8.  Treatment resistant hypertension--investigation and conservative management.

Authors:  Franz Weber; Manfred Anlauf
Journal:  Dtsch Arztebl Int       Date:  2014-06-20       Impact factor: 5.594

9.  Prolonged activation of the baroreflex produces sustained hypotension.

Authors:  Thomas E Lohmeier; Eric D Irwin; Martin A Rossing; David J Serdar; Robert S Kieval
Journal:  Hypertension       Date:  2004-01-05       Impact factor: 10.190

10.  Resistant hypertension: diagnosis, evaluation, and treatment. A scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research.

Authors:  David A Calhoun; Daniel Jones; Stephen Textor; David C Goff; Timothy P Murphy; Robert D Toto; Anthony White; William C Cushman; William White; Domenic Sica; Keith Ferdinand; Thomas D Giles; Bonita Falkner; Robert M Carey
Journal:  Hypertension       Date:  2008-04-07       Impact factor: 10.190

View more
  2 in total

Review 1.  Preferred Fourth-Line Pharmacotherapy for Resistant Hypertension: Are We There Yet?

Authors:  Hamish Cg Prosser; Cynthia Gregory; Dagmara Hering; Graham S Hillis; Greg Perry; Johan Rosman; Carl Schultz; Mark Thomas; Gerald F Watts; Markus P Schlaich
Journal:  Curr Hypertens Rep       Date:  2017-04       Impact factor: 5.369

Review 2.  [Invasive treatment of hypertension : Update 2016].

Authors:  J Menne; R Wachter
Journal:  Internist (Berl)       Date:  2016-09       Impact factor: 0.743

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.